"A predictive biomarker is like a "check engine" light on your dashboard. It warns you that there is a risk of a future problem. In this study, the researchers only checked if the drug turned off the "check engine" light (by measuring blood proteins), rather than testing if the car was actually driving properly (by testing the patients' actual memory and brain function)."

Always do FIRST analysis on studies. Or have AI do it for you. I used Gemini to dig into this:

"Novo Nordisk funded this study, and several of the researchers are employees or minor shareholders. While corporate funding doesn't automatically mean the data is fabricated, it does mean the company is highly motivated to find and publish data that makes their blockbuster drug (semaglutide, marketed as Wegovy, Ozempic, and Rybelsus) look like a preventative treatment for a wider range of conditions, expanding its market and driving up profits."

"Funding: The study was funded by Novo Nordisk A/S.

Investigation: Researchers conducted a post hoc analysis using data from the randomized, placebo-controlled SELECT trial. They applied the Dementia SomaSignal Test (dSST)—a 25-protein risk score—to non-fasted serum samples collected at baseline and at week 104 to estimate 5-year and 20-year all-cause dementia risk in patients receiving semaglutide (2.4 mg) versus a placebo.

Results: Semaglutide significantly attenuated the progression of the dementia risk signature. Compared to the placebo group, the 5-year predicted risk increased 2.5-fold less (a 26.0% lower predicted event rate) and the 20-year risk increased 1.67-fold less (an 8.8% lower rate). Semaglutide also lowered the odds of patients moving into a higher dementia risk category by 36%.

Subjects: The analysis included 2,970 older adults aged 65 and older (mean age of ~69.7 years) who had overweight or obesity and cardiovascular disease, but no history of diabetes. The cohort consisted of 814 women (27.4%) and 2,156 men (72.6%).

Time: The study evaluated data over a 104-week (2-year) follow-up period. The analysis was published on August 8, 2026."

And then map the weakness to each respective letter if you want to dig deeper.

I really hope at some point we can 'option click' or whatever, and choose multiple threads to archive. It takes FOREVER to archive the cluttery chats one by one. That's my one wish feature, please make batch cleanup of my client reasonably easy. Imagine having to delete one file at a time in a folder of 50 plus files. Barf.

If you're looking for a domain where the 70% AI solution is a total failure, that's the field. You can't rely on vibe coding because the underlying math, like Learning With Errors (LWE) or supersingular isogeny graphs, is conceptually dense and hasn't been commoditized into AI training data yet. It requires that same 'several-day-soak' thinking you loved in physics, specifically because we're trying to build systems that remain secure even against an adversary with a quantum computer. It’s one of the few areas left where the Thinker isn't just a luxury, but a hard requirement for the Builder to even begin.

Just use tasks.google.com

Add your todos, when finished, type DONE in front of it, this way it' a journal and you get to feel good about all the things you've done since you're always looking at your list. Anything without a DONE needs to be done. You can write details in each entry, too.

No subscriptions, no fees, accessible from your phone, computer. etc. Keep it simple, folks.